REGEnLIFE develops medical devices utilizing Tri-Photonique stimulation technology to target neuroinflammation associated with neurodegenerative diseases such as Alzheimer's and concussions. Their approach offers a non-invasive, drug-free treatment option aimed at improving neurological health and addressing the growing prevalence of these conditions.
Funding
$14.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like Alzheimer's and concussions are associated with neuroinflammation, which contributes to neuronal damage and cognitive decline. Current treatment options often involve pharmaceuticals with potential side effects, and non-invasive, drug-free alternatives are limited. Effective methods for targeting neuroinflammation directly are needed to improve neurological health.
Solution
REGEnLIFE develops medical devices that utilize Tri-Photonique stimulation technology to address neuroinflammation associated with various neurological conditions. This technology employs specific light parameters to modulate cellular activity and reduce inflammation in the brain and gut. The devices offer a non-invasive and non-pharmaceutical approach to stimulate the brain and intestines simultaneously. By targeting the neuroinflammation, REGEnLIFE aims to provide a novel therapeutic option for patients suffering from neurodegenerative diseases and other neurological disorders.
Target Audience
The primary target audience includes individuals suffering from neurodegenerative diseases such as Alzheimer's, those with concussions, and individuals with other neurological conditions associated with neuroinflammation.
Features
- Tri-Photonique stimulation technology targeting neuroinflammation
- Non-invasive and drug-free treatment approach
- Medical devices designed for simultaneous stimulation of the brain and intestines
- Photobiomodulation technology to modulate cellular activity
- Clinical trials evaluating the efficacy in Alzheimer's disease
- Devices targeting neuroinflammation associated with concussions and depression